CN1202931A - 肿瘤疫苗及其制备方法 - Google Patents

肿瘤疫苗及其制备方法 Download PDF

Info

Publication number
CN1202931A
CN1202931A CN96198493A CN96198493A CN1202931A CN 1202931 A CN1202931 A CN 1202931A CN 96198493 A CN96198493 A CN 96198493A CN 96198493 A CN96198493 A CN 96198493A CN 1202931 A CN1202931 A CN 1202931A
Authority
CN
China
Prior art keywords
peptide
cell
tumour
patient
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96198493A
Other languages
English (en)
Chinese (zh)
Inventor
沃尔特·施米特
马克斯·伯恩斯蒂尔
塔马斯·施韦格霍弗
彼得·斯坦雷恩
迈克尔·布希里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN1202931A publication Critical patent/CN1202931A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN96198493A 1995-11-23 1996-11-21 肿瘤疫苗及其制备方法 Pending CN1202931A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19543649.0 1995-11-23
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044.9 1996-11-25

Publications (1)

Publication Number Publication Date
CN1202931A true CN1202931A (zh) 1998-12-23

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96198493A Pending CN1202931A (zh) 1995-11-23 1996-11-21 肿瘤疫苗及其制备方法

Country Status (24)

Country Link
US (1) US20020085997A1 (cg-RX-API-DMAC7.html)
EP (1) EP0866851A1 (cg-RX-API-DMAC7.html)
JP (1) JP2000502052A (cg-RX-API-DMAC7.html)
KR (1) KR19990067653A (cg-RX-API-DMAC7.html)
CN (1) CN1202931A (cg-RX-API-DMAC7.html)
AR (1) AR004341A1 (cg-RX-API-DMAC7.html)
AU (1) AU720131B2 (cg-RX-API-DMAC7.html)
BG (1) BG62999B1 (cg-RX-API-DMAC7.html)
BR (1) BR9611466A (cg-RX-API-DMAC7.html)
CA (1) CA2238176A1 (cg-RX-API-DMAC7.html)
CO (1) CO4520254A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ158998A3 (cg-RX-API-DMAC7.html)
EE (1) EE03778B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0000318A3 (cg-RX-API-DMAC7.html)
NO (1) NO982329D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ322910A (cg-RX-API-DMAC7.html)
PL (1) PL188537B1 (cg-RX-API-DMAC7.html)
RO (1) RO115275B1 (cg-RX-API-DMAC7.html)
RU (1) RU2206329C2 (cg-RX-API-DMAC7.html)
SK (1) SK66998A3 (cg-RX-API-DMAC7.html)
TR (1) TR199800912T2 (cg-RX-API-DMAC7.html)
TW (1) TW514530B (cg-RX-API-DMAC7.html)
UY (2) UY24367A1 (cg-RX-API-DMAC7.html)
WO (1) WO1997019169A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
CN101287754B (zh) * 2005-09-05 2013-02-13 伊玛提克斯生物技术有限公司 混杂地结合于人类白细胞抗原(hla)ⅱ类分子的肿瘤相关肽

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) † 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE69839273T2 (de) 1997-01-31 2009-03-05 Edward P. Chicago Cohen Krebsimmuntherapie mit semi-allogenen zellen
ATE284707T1 (de) * 1997-08-22 2005-01-15 Science Park Raf S P A Tumorvakzinierung mittels verwendung autologer oder hla-verwandter antigen präsentierender zellen (apc), die mit einem tumorantigen sowie einem eine immunantwort hervorrufenden fremdantigen transduziert sind
CA2322660A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
EP2192407A3 (en) * 2001-09-18 2011-04-27 Green Peptide Co., Ltd. Method of detecting cellular immunity and application thereof to drugs
RU2203683C1 (ru) * 2001-09-20 2003-05-10 НИИ онкологии им. проф. Н.Н. Петрова Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
US7579452B2 (en) * 2003-08-25 2009-08-25 Oncomune, Llc Cancer vaccine based on brother of regulator of imprinted sites molecule
RU2267326C2 (ru) * 2004-03-16 2006-01-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
ES2440481T3 (es) * 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
EP1871166A4 (en) 2005-03-29 2008-11-12 Univ Illinois CARCINOMAS AND THERAPEUTIC PROCEDURES
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
JP6710004B2 (ja) 2016-03-15 2020-06-17 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
CN110612116A (zh) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 甲病毒新抗原载体
TW202523847A (zh) 2019-05-30 2025-06-16 美商磨石生物公司 經修飾之腺病毒
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
WO2022192701A1 (en) * 2021-03-12 2022-09-15 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
EP0569678A3 (de) * 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
CN101287754B (zh) * 2005-09-05 2013-02-13 伊玛提克斯生物技术有限公司 混杂地结合于人类白细胞抗原(hla)ⅱ类分子的肿瘤相关肽

Also Published As

Publication number Publication date
CA2238176A1 (en) 1997-05-29
CO4520254A1 (es) 1997-10-15
NZ322910A (en) 2000-05-26
RU2206329C2 (ru) 2003-06-20
EP0866851A1 (de) 1998-09-30
HUP0000318A3 (en) 2002-02-28
EE9800161A (et) 1998-12-15
EE03778B1 (et) 2002-06-17
BG102439A (en) 1999-01-29
RO115275B1 (ro) 1999-12-30
WO1997019169A1 (de) 1997-05-29
TR199800912T2 (xx) 1998-08-21
AU7694796A (en) 1997-06-11
PL326756A1 (en) 1998-10-26
BG62999B1 (bg) 2001-01-31
AU720131B2 (en) 2000-05-25
UY24367A1 (es) 2000-10-31
HUP0000318A2 (hu) 2000-06-28
JP2000502052A (ja) 2000-02-22
TW514530B (en) 2002-12-21
NO982329D0 (no) 1998-05-22
KR19990067653A (ko) 1999-08-25
CZ158998A3 (cs) 1999-06-16
AR004341A1 (es) 1998-11-04
SK66998A3 (en) 1998-12-02
BR9611466A (pt) 1999-05-18
PL188537B1 (pl) 2005-02-28
US20020085997A1 (en) 2002-07-04
UY24430A1 (es) 1997-07-01

Similar Documents

Publication Publication Date Title
CN1202931A (zh) 肿瘤疫苗及其制备方法
Gilboa The makings of a tumor rejection antigen
Livingston et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes
Irvine et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
JP4764874B2 (ja) Ｍｈｃ分子を結合する腫瘍関連ペプチド
JP2019502360A (ja) Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
CN1309417C (zh) 穿细胞肽在产生抗肿瘤免疫力上的用途
El Hage et al. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway
Ribas et al. Intra–lymph node prime-boost vaccination against melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial
JP2018531581A (ja) 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
KR19990082601A (ko) 펩티드 및 애쥬번트에 기초한 면역조절용 약제학적 조성물
EP2027150B1 (en) Allorestricted peptide-specific t cells
Zhang et al. Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses
CN1893925A (zh) 树突细胞的体内靶向
Hansen et al. Basic and translational applications of engineered MHC class I proteins
KR20210025534A (ko) 암에 대한 면역요법에 사용하기 위한 a*03 제한 펩티드 및 관련 방법
Hos et al. Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA
Zhang et al. A polyclonal anti‐vaccine CD4 T cell response detected with HLA‐DP4 multimers in a melanoma patient vaccinated with MAGE‐3. DP4‐peptide‐pulsed dendritic cells
Almunia et al. Bee venom phospholipase A2, a good “chauffeur” for delivering tumor antigen to the MHC I and MHC II peptide-loading compartments of the dendritic cells: the case of NY-ESO-1
Matheoud et al. Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model
WO1995027505A1 (en) Cellular immune response-specific antigens and uses therefor
CN1379041A (zh) 细胞毒性t淋巴细胞
Sennikov et al. Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A* 02: 01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients
Borobova et al. Design of artificial immunogens containing melanoma-associated T-cell epitopes
JP2002506633A (ja) Ｔ細胞応答を誘発するための遺伝子に基づくワクチンの組成物および使用法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication